“…One study was originally included, but was later retracted due to concerns about data integrity, and thus was excluded [ 42 ]. Antiviral treatments compared in the included studies were umifenovir (Arbidol) [ 25 , 29 , 31 , 47 ], baloxavir marboxil [ 30 ], enisamium [ 50 ], favipiravir [ 25 , 30 , 35 , 40 – 42 , 44 , 45 , 48 , 52 ], lopinavir/ritonavir (LPV/r) [ 24 , 26 , 27 , 29 , 31 , 37 , 38 , 44 , 47 ], remdesivir [ 23 , 34 , 36 , 39 , 51 , 53 ], ribavirin [ 22 ], sofosbuvir/daclatasvir [ 22 , 32 , 33 , 46 , 49 ], sofosbuvir/ledipasvir [ 28 ], sofosbuvir/ravidasvir [ 46 ], and sofosbuvir/velpatasvir [ 43 ]. The study characteristics and baseline patient characteristics are summarized in Table 2 .…”